口头报告-早期乳腺癌
日期:2023年10月20日 星期五
时间:14:00 - 15:40
主席:Stephen R. Johnston (London, United Kingdom),Sara M. Tolaney (Boston, United States of America)
地点:Bilbao Auditorium - NCC
摘要号:LBA17
标题:Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
辅助使用阿贝马西利布联合内分泌治疗治疗HR+、HER2-、高危早期乳腺癌:来自预先计划的MonarchE全生存中期分析的结果,包括5年疗效结果。
报告人:Nadia Harbeck (Munich, Germany)
时间:14:00 - 14:10
摘要号:LBA18
标题:Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase 3 KEYNOTE-522 study
早期三阴性乳腺癌的帕博利珠单抗或安慰剂联合化疗后使用帕博利珠单抗或安慰剂的治疗:基于第三期KEYNOTE-522研究的更新事件无进展生存结果。
报告人:Peter Schmid (London, United Kingdom)
时间:14:10 - 14:20
摘要号:LBA19
标题:Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study
高危三阴性乳腺癌(TNBC)新辅助紫杉醇/卡铂联合阿替唑酮治疗与不联合阿替唑酮治疗后,采用辅助蒽环类药物方案的无事件生存(EFS)分析:NeoTRIP Miacheangelo随机研究。
报告人:Luca Gianni (Milan, Italy)
时间:14:20 - 14:30
摘要号:LBA20
标题:A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)
一项随机、双盲试验,比较新沙替尼(NIVO)与安慰剂(PBO)在新辅助化疗(NACT)后联合使用辅助内分泌治疗(ET)±NIVO治疗高风险ER+ HER2-原发性乳腺癌(BC)患者(pts)的疗效。
报告人:Sherene Loi (Melbourne, Australia)
时间:14:55 - 15:05
摘要号:LBA21
标题:KEYNOTE-756: Phase 3 study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer
KEYNOTE-756:对早期高风险ER+/HER2-乳腺癌进行新辅助帕博利珠单抗(pembro)或安慰剂(pbo)+化疗(chemo)后,接受辅助帕博利珠单抗或安慰剂+p内分泌治疗(ET)的第三期研究。
报告人:Fatima Cardoso (Lisbon, Portugal)
时间:15:05 - 15:15
迷你口头报告-早期乳腺癌
日期:2023年10月23日 星期一
时间:16:30 - 18:00
主席:Ines V. Vaz Luis (Villejuif, Cedex, France) ,Carsten Denkert (Marburg, Germany), Ava Kwong (Hong Kong, Hong Kong PRC)
地点:Bilbao Auditorium - NCC
摘要号:238MO
标题:Longterm residential and workplace exposure to air pollution and breast cancer risk: a case-control study nested in the French E3N cohort from 1990 to 2011
长期居住和工作环境对空气污染的暴露与乳腺癌风险:一项嵌套在法国E3N队列研究中的病例对照研究,时间跨度为1990年至2011年。
报告人:Beatrice Fervers (Lyon, France)
时间:16:30 - 16:35
摘要号:LBA22
标题:Connected device and therapeutic patient education to promote physical activity among in women with localized breast cancer: results from the DISCO randomized trial
通过连接设备和治疗性患者教育来促进局部乳腺癌妇女的体力活动:来自DISCO随机试验的结果。
报告人:Beatrice Fervers (Lyon, France)
时间:16:35 - 16:40
摘要号:239MO
标题:Impact of body mass index and its change on survival outcomes in patients with early breast cancer: a pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials
体重指数及其变化对早期乳腺癌患者生存结果的影响:基于BCIRG-001和BCIRG-005试验的个体水平数据的汇总分析。
报告人:陈海珠(中国,广州)
时间:16:40 - 16:45
摘要号:240MO
标题:Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: an exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC)
雌激素/孕激素受体(ER/PR)和Ki-67表达的预后和预测性影响:基于MonarchE试验在高危风险、HR+、HER2-早期乳腺癌(EBC)患者中的探索性分析。
报告人:Matthew P. Goetz (Rochester, United States of America)
时间:17:00 - 17:05
摘要号:LBA23
标题:Invasive disease–free survival (iDFS) across key subgroups from the Phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC)
来自RIB联合非甾体类芳香酶抑制剂(NSAI)在HR+/HER2-早期乳腺癌(EBC)患者中的Phase III NATALEE研究的关键亚组的侵袭性疾病无进展生存(iDFS)结果。
报告人:Aditya Bardia (Boston, United States of America)
时间:17:05 - 17:10
摘要号:241MO
标题:Patient characteristics and real-world outcomes in HER2 negative/ ER zero and ER low patients treated as triple-negative breast cancer in Sweden 2008-2020
病患特征和在瑞典2008-2020年期间作为三阴性乳腺癌接受治疗的HER2阴性/ER阴性和ER低患者的实际临床结果。
报告人:Irma Fredriksson (Stockholm, Sweden)
时间:17:10 - 17:15
摘要号:242MO
标题:Association of tumor-infiltrating lymphocytes (TILs) with Recurrence Score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC) - a translational analysis of four prospective multicentric studies.
肿瘤浸润淋巴细胞(TILs)与激素受体阳性(HR+)/HER2阴性(HER2-)早期乳腺癌(BC)患者中的复发评分(RS)相关性——基于四项前瞻性多中心研究的转化分析。
报告人:Federica Miglietta (Padova, Italy)
时间:17:15 - 17:20
摘要号:LBA24
标题:Multiparametric prognostic score in early HR+/HER2- breast cancer: impact of Recurrence Score, clinical-pathological factors, gene mutations and histology
早期HR+/HER2-乳腺癌的多参数预后评分:复发评分、临床病理因素、基因突变和组织学的影响。
报告人:Oleg Gluz (Mönchengladbach, Germany)
时间:17:20 - 17:25
摘要号:243MO
标题:Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: three-year preplanned primary-endpoint on a phase 2 multicentre prospective trial
新辅助全身治疗后,对浸润性癌症进行乳腺手术的省略:一项多中心前瞻性试验的三年预先计划的主要终点结果(2期)。
报告人:Henry M. Kuerer (Houston, United States of America)
时间:17:40 - 17:45
摘要号:244MO
标题:A Phase II Trial Targeting Disseminated Dormant Tumor Cells with Hydroxychloroquine, Everolimus or the Combination to Prevent Recurrent Breast Cancer (“CLEVER”)
针对使用羟氯喹、依维莫司或两者联合治疗来预防复发性乳腺癌的扩散潜伏肿瘤细胞的II期临床试验(“CLEVER”)。
报告人:Angela DeMichele (Philadelphia, United States of America)
时间:17:45 - 17:50
口头报告-转移性乳腺癌
日期:2023年10月21日 星期六
时间:10:15 - 11:35
主席:Hervé Bonnefoi (Bordeaux, France), Janice Wing-Hang Tsang (Hong Kong, Hong Kong PRC)
地点:Barcelona Auditorium - Hall 9
摘要号:381O
标题:First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors
HS-20089是B7-H4抗体药物复合物(ADC),在晚期实体肿瘤患者中进行的首个人体/1期临床试验。
报告人:张剑(中国,上海)
时间:10:15 - 10:25
摘要号:376O
标题:Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase 3 DESTINY-Breast04 study
曲妥珠单抗-德来曲塞康(T-DXd)与医生选择的治疗(TPC)在HER2低表达不可切除和/或转移性乳腺癌(mBC)患者中的对比:DESTINY-Breast04随机、3期研究的更新生存结果。
报告人:Shanu Modi (New York, United States of America)
时间:10:25 - 10:35
摘要号:377O
标题:A Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2-Positive (HER2+) Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03
DESTINY-Breast (DB)-01、-02和-03中T-DXd在HER2阳性(HER2+)转移性乳腺癌(mBC)伴有脑转移病灶(BMs)的患者(pts)的群体分析。
报告人:Sara A. Hurvitz (Santa Monica, United States of America)
时间:10:55 - 11:05
摘要号:378O
标题:Persistence under abemaciclib and endocrine treatment (ABA+ET) in patients with advanced breast cancer (aBC) – first results of the randomized IMPACT Trial comparing patient coaching with the MASCC Oral Agent Teaching Tool (MOATT) versus local routine patient coaching (LC).
在晚期乳腺癌患者中,阿贝马西利布和内分泌治疗(ABA+ET)的持久性——比较使用MASCC口服药物教育工具(MOATT)的患者辅导与当地常规患者辅导的IMPACT随机试验的首次结果。
报告人:Manfred K. Welslau (Aschaffenburg, Germany)
时间:11:05 - 11:15
迷你口头报告-转移性乳腺癌
日期:2023年10月22日 星期日
时间:08:30 - 09:55
主席:Barbara Pistilli (Villejuif, Cedex, France), Christoph Thomssen (Halle, Germany), Hervé Bonnefoi (Bordeaux, France)
地点:Bilbao Auditorium - NCC
摘要号:379MO
标题:Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study
Datopotamab deruxtecan(Dato-DXd)+durvalumab(D)作为不可切除的局部晚期/转移三阴性乳腺癌(a/mTNBC)的一线(1L)治疗:BEGONIA的更新结果,一项1b/2期研究。
报告人:Peter Schmid (London, United Kingdom)
时间:08:30 - 08:35
摘要号:380MO
标题:SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): results from a phase I/II, single-arm, basket trial
SKB264(MK-2870)在先前治疗过的激素受体阳性(HR+)/HER2阴性转移性乳腺癌(mBC)中的研究结果:来自一项1/2期、单臂、篮子试验。
报告人:殷咏梅(中国,南京)
时间:08:35 - 08:40
摘要号:382MO
标题:Updated results from the phase 1/2 study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD ) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer.
OP-1250,一种口服的完全雌激素受体(ER)拮抗剂(CERAN)和选择性ER降解剂(SERD)在晚期或转移性ER阳性、HER2阴性乳腺癌患者(pts)中的1/2期研究的更新结果。
报告人:Nancy U. Lin (Boston, United States of America)
时间:08:55 - 09:00
摘要号:383MO
标题:Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase 1a/b EMBER study
Imlunestrant联合依维莫司或阿帕替利栓,用于ER+、HER2-晚期乳腺癌(aBC):来自1a/b期EMBER研究的结果。
报告人:Komal Jhaveri (New York, United States of America)
时间:09:00 - 09:05
摘要号:384MO
标题:Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naïve, hormone receptor-positive (HR+) advanced breast cancer (FALCON)
FALCON研究中对于未接受内分泌治疗(ET-naïve)的激素受体阳性(HR+)晚期乳腺癌患者,富劳酮与阿那曲唑在总体生存期方面的最终分析。
报告人:John Robertson (Nottingham, United Kingdom)
时间:09:05 - 09:10
摘要号:385MO
标题:A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors
DP303c在预先治疗过的HER2阳性晚期实体肿瘤患者中的多中心、开放标签、剂量递增和扩展研究。
报告人:杜益群(中国,上海)
时间:09:25 - 09:30
摘要号:386MO
标题:Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase III TULIP trial
TULIP试验中Trastuzumab duocarmazine与医生选择治疗在预先治疗过的HER2阳性转移性乳腺癌中的比较:最终结果的III期试验。
报告人:Philippe G. Aftimos (Anderlecht, Belgium)
时间:09:30 - 09:35
摘要号:387MO
标题:First Results of the SOLTI-1903 HOPE's Patient-Centric Molecular Screening Program in Advanced Breast Cancer
STI-1903 HOPE患者中心的分子筛计划在晚期腺癌中的首次结果公布。
报告人:Tomás Pascual (Barcelona, Spain)
时间:09:35 - 09:40
编辑:Potato